A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumours

Official Title

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects With Advanced Stage Solid Tumours

Summary:

The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-6389808.

Trial Description

Primary Outcome:

  • Part 1 and Part 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
  • Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
  • Part 1: Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Secondary Outcome:
  • Part 1 and Part 2: Serum Concentrations of JNJ-63898081
  • Part 1 and 2: Systemic Cytokine Concentrations
  • Part 1 and 2: Concentration of Markers of T-Cell Activation
  • Part 1 and 2: Number of Participants with JNJ-63898081 Antibodies
  • Serum Prostate Specific Antigen (PSA) Concentration
  • Percentage of JNJ-63898081 Receptor Occupancy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society